We have developed three new monoclonal antibodies specific to BNP. BNP is an established cardiac biomarker and it is used as a diagnostic and prognostic marker of heart failure. Heart failure is a severe health problem that is characterized by an increasing prevalence and economic cost.

We now provide eight MAbs specific to BNP (see Figure 1).

Figure 1.

The new MAbs, 100cc, 130cc and 429cc can be used in combination with our other anti-BNP MAbs. Recommended MAb pairs for conventional BNP immunoassays are provided in Table 1.


Table 1.

MAb combination 57H3-429 and 50E1-130 show good correlation with commercially available assays (see Figure 2).

Figure 2.

More details of our product offering and data on their performance is available in the updated Human proBNP, BNP and NT-proBNP TechNotes.

Read the updated Human proBNP, BNP and NT-proBNP TechNotes